HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

M Jongen-Lavrencic Selected Research

Therapeutics

5/2015Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


M Jongen-Lavrencic Research Topics

Disease

2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2016 - 12/2015
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2016 - 05/2015
1Multiple Myeloma
11/2011
1B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
05/2008
1BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
03/2005
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
12/2003
1Stevens-Johnson Syndrome (Lyell's Syndrome)
12/2003

Drug/Important Bio-Agent (IBA)

3MicroRNAs (MicroRNA)IBA
01/2016 - 05/2008
2Azacitidine (5 Azacytidine)FDA Link
01/2016 - 12/2015
1Immunoglobulin Heavy Chains (Immunoglobulin Heavy Chain)IBA
05/2008
1Oncogene Proteins (Oncogene Protein)IBA
03/2005
1Ciprofloxacin (Cipro)FDA LinkGeneric
12/2003

Therapy/Procedure

1Therapeutics
05/2015